A conceptual and methodological framework for investigating etiologic heterogeneity

Statistics in Medicine

Volumn 32, Issue 29, 2013, Pages 5039-5052

  Begg, Colin B ^a   Zabor, Emily C ^a   Bernstein, Jonine L ^a   Bernstein, Leslie ^b   Press, Michael F ^c   Seshan, Venkatraman E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer epidemiology; Clustering; Etiologic heterogeneity

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ANALYTICAL RESEARCH; ARTICLE; CANCER CLASSIFICATION; CARCINOGENESIS; CONCEPTUAL FRAMEWORK; DISEASE PREDISPOSITION; FAMILY HISTORY; GENE EXPRESSION; GENETIC HETEROGENEITY; MATHEMATICAL ANALYSIS; MATHEMATICAL VARIABLE; MENARCHE; METHODOLOGY; MOLECULAR GENETICS; POPULATION RISK; SOMATIC MUTATION; TAXONOMY; VALIDATION PROCESS;

CANCER EPIDEMIOLOGY; CLUSTERING; ETIOLOGIC HETEROGENEITY;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887234628     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5902     Document Type: Article

References (36)

1. Harris TJ, McCormick F. The molecular pathology of cancer. Nature Reviews Clinical Oncology 2010; 7:251-265. DOI: 10.1038/nrclinonc.2010.41.
2. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics 2010; 42:715-721. DOI: 10.1038/ng.619.
3. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11-22. DOI: 10.1016/j.ccr.2010.05.026.
4. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Genetics 2007; 39:870-874. DOI: 10.1038/ng2075.
5. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087-1093. DOI: 10.1038/nature05887.
6. Troester MA, Swift-Scanlan T. Challenges in studying the etiology of breast cancer subtypes. Breast Cancer Research 2009; 11:104. DOI: 10.1186/bcr2323.
7. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. Journal of Pathology 1999; 187:8-18. DOI: 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y.
8. Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ, Taylor JA. Hepatitis B aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiology, Biomarkers & Prevention 2001; 10:617-625.
9. Kelsey KT, Hirao T, Hirao S, Devi-Ashok T, Nelson HH, Andrew A et al. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. International Journal of Cancer 2005; 117:370-375. DOI: 10.1002/ijc.21195.
10. Marsit CJ, Christensen BC, Houseman EA, Karagas MR, Wrensch MR, Yeh RF et al. Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis 2009; 30:416-422. DOI: 10.1093/carcin/bgp006.
11. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiology, Biomarkers & Prevention 2004; 13:1558-1568.
12. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. Journal of the National Cancer Institute 2011; 103:250-263. DOI: 10.1093/jnci/djq526.
13. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008; 113:1521-1526. DOI: 10.1002/cncr.23786.
14. Reeves GK, Travis RC, Green J, Bull D, Tipper S, Baker K et al. Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. JAMA: The Journal of the American Medical Association 2010; 304:426-434. DOI: 10.1001/jama.2010.1042.
15. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clinical Cancer Research 2008; 14:8000-8009. DOI: 10.1158/1078-0432.CCR-08-0975.
16. Lloyd SP. Least squares quantization in PCM. Technical Note, Bell Laboratories 1957. Published in 1982 in IEEE Transactions on Information Theory 1982; 28:128-137.
17. Hartigan JA, Wong MA. A K-means clustering algorithm. Applied Statistics 1979; 28:100-108.
18. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001; 98:10869-10874. DOI: 10.1073/pnas.191367098.
19. Cancer and Steroid Hormone Study Investigators. Oral-contraceptive use and the risk of breast cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. New England Journal of Medicine 1986; 315:405-411. DOI: 10.1056/NEJM198608143150701.
20. Wingo PA, Ory HW, Layde PM, Lee NC. The evaluation of the data collection process for a multicenter, population-based, case-control design. American Journal of Epidemiology 1988; 128:206-217.
21. Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L et al. The NICHD womens' contraceptive and reproductive experiences study: methods and operational results. Annals of Epidemiology 2002; 12:213-221. DOI: 10.1016/S1047-2797(01)00274-5.
22. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Research 2010; 70:575-587. DOI: 10.1158/0008-5472.CAN-09-3460.
23. Thompson WD. Statistical analysis of case-control studies. Epidemiologic Reviews 1994; 16:33-50.
24. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Research and Treatment 2011; 130:587-597. DOI: 10.1007/s10549-011-1616-x.
25. Bair E, Tibshirani R.Semi-supervised methods to predict patient survival from gene expression data. PLOS Biology 2004 Apr; 2(4):E108.
26. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology 2011; 24:157-167. DOI: 10.1038/modpathol.2010.200.
27. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology 2009; 27:1160-1167. DOI: 10.1200/JCO.2008.18.1370.
28. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012; 490:61-70. DOI: 10.1038/nature11412.
29. Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes & Control 1999; 10:431-437. DOI: 10.1023/A:100897012159528.
30. Tarone RE, Chu KC. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes & Control 2002; 13:7-14. DOI: 10.1023/a:1013960609008.
31. van der Kooy K, Rookus MA, Peterse HL, van Leeuwen FE. p53 protein overexpression in relation to risk factors for breast cancer. American Journal of Epidemiology 1996; 144:924-933.30.
32. Furberg H, Millikan RC, Geradts J, Gammon MD, Dressler LG, Ambrosone CB et al. Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States). Cancer Causes & Control 2003; 14:609-618. DOI: 10.1023/A:1025682410937.
33. Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA et al. Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women. Cancer Epidemiology Biomarkers & Prevention 1999; 8:225-263.
34. Seshan VE, Gonen M, Begg CB. Comparing ROC curves derived from regression models. Statistics in Medicine 2013; 32:1483-1493. DOI: 10.1002/sim.5648.
35. Begg CB. A strategy for distinguishing optimal cancer subtypes. International Journal of Cancer 2011; 129:931-937. DOI: 10.1002/ijc.25714.
36. Begg CB, Zabor EC. Detecting and exploiting etiologic heterogeneity in epidemiologic studies. American Journal of Epidemiology 2012; 176:512-518. DOI: 10.1093/aje/kws128.